KRAS and non-small cell lung carcinoma: Evaluating the 12-month progression free survival (PFS), the best outcome to ICI therapy was found in NSCLC patients with KRAS and MET mutations, who achieved the highest 12-month PFS (25.6% and 23.4%, respectively); NSCLC patients with the HER2 mutation exhibited an intermediate outcome (18.0%), and those with the RET, EGFR, ALK, and ROS1 mutations exhibited the poorest 12-month PFS outcomes (7.0%, 6.4%, 5.9%, and unevaluable due to small numbers, respectively) [62].